Thompson Davis & Co’s CapForce IBD 50 ETF FFTY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-24,300
Closed -$575K 125
2023
Q1
$575K Buy
24,300
+250
+1% +$5.74K 0.75% 27
2022
Q4
$525K Hold
24,050
0.75% 26
2022
Q3
$588K Hold
24,050
0.8% 22
2022
Q2
$646K Hold
24,050
1.06% 19
2022
Q1
$940K Hold
24,050
1.15% 18
2021
Q4
$1.1M Buy
+24,050
New +$1.15M 0.92% 18
2018
Q3
$947K Hold
24,625
2.07% 4
2018
Q2
$864K Buy
24,625
+125
+0.5% +$4.36K 2.06% 4
2018
Q1
$816K Sell
24,500
-733
-3% -$25K 2.15% 4
2017
Q4
$837K Buy
25,233
+1,183
+5% +$39.3K 1.98% 6
2017
Q3
$761K Hold
24,050
1.35% 8
2017
Q2
$654K Hold
24,050
1.05% 16
2017
Q1
$616K Buy
+24,050
New +$601K 0.88% 24

Other funds holding FFTY

Thompson Davis & Co's FFTY Position: Q2 2023 in Review

Thompson Davis & Co sold out of CapForce IBD 50 ETF (FFTY) in Q2 2023, closing a stake of 24,300 shares — an estimated $575K sold.

Thompson Davis & Co first reported a position in FFTY in Q1 2017 and held it in 13 quarters. The position peaked at $1.1M in Q4 2021. 45 funds tracked by Wall St. Rank hold FFTY as of Q2 2023.

  • Thompson Davis & Co reported no remaining CapForce IBD 50 ETF position as of Q2 2023 after selling out during the quarter.
  • Thompson Davis & Co sold 24,300 CapForce IBD 50 ETF shares in Q2 2023, an estimated $575K.
  • Thompson Davis & Co first reported a position in CapForce IBD 50 ETF in Q1 2017 and held it in 13 quarters.
  • Thompson Davis & Co's CapForce IBD 50 ETF position peaked at $1.1M in Q4 2021.
  • 45 funds tracked by Wall St. Rank held CapForce IBD 50 ETF as of Q2 2023.

Based on Thompson Davis & Co's 13F filing for Q2 2023, filed 13 Jul 2023.